240 related articles for article (PubMed ID: 17219455)
1. The complete structure and pro-inflammatory activity of the lipooligosaccharide of the highly epidemic and virulent gram-negative bacterium Burkholderia cenocepacia ET-12 (strain J2315).
Silipo A; Molinaro A; Ieranò T; De Soyza A; Sturiale L; Garozzo D; Aldridge C; Corris PA; Khan CM; Lanzetta R; Parrilli M
Chemistry; 2007; 13(12):3501-11. PubMed ID: 17219455
[TBL] [Abstract][Full Text] [Related]
2. The structure and proinflammatory activity of the lipopolysaccharide from Burkholderia multivorans and the differences between clonal strains colonizing pre and posttransplanted lungs.
Ieranò T; Silipo A; Sturiale L; Garozzo D; Brookes H; Khan CM; Bryant C; Gould FK; Corris PA; Lanzetta R; Parrilli M; De Soyza A; Molinaro A
Glycobiology; 2008 Nov; 18(11):871-81. PubMed ID: 18684854
[TBL] [Abstract][Full Text] [Related]
3. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans.
Mahenthiralingam E; Vandamme P; Campbell ME; Henry DA; Gravelle AM; Wong LT; Davidson AG; Wilcox PG; Nakielna B; Speert DP
Clin Infect Dis; 2001 Nov; 33(9):1469-75. PubMed ID: 11588691
[TBL] [Abstract][Full Text] [Related]
4. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence.
Drevinek P; Mahenthiralingam E
Clin Microbiol Infect; 2010 Jul; 16(7):821-30. PubMed ID: 20880411
[TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide chemotypes of Burkholderia cepacia.
Evans E; Poxton IR; Govan JRW
J Med Microbiol; 1999 Sep; 48(9):825-832. PubMed ID: 10482293
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of Burkholderia cepacia isolates from cystic fibrosis (CF) patients in an Italian CF center.
Petrucca A; Cipriani P; Valenti P; Santapaola D; Cimmino C; Scoarughi GL; Santino I; Stefani S; Sessa R; Nicoletti M
Res Microbiol; 2003 Sep; 154(7):491-8. PubMed ID: 14499935
[TBL] [Abstract][Full Text] [Related]
7. Structural study and conformational behavior of the two different lipopolysaccharide O-antigens produced by the cystic fibrosis pathogen Burkholderia multivorans.
Ieranò T; Silipo A; Cescutti P; Leone MR; Rizzo R; Lanzetta R; Parrilli M; Molinaro A
Chemistry; 2009 Jul; 15(29):7156-66. PubMed ID: 19533713
[TBL] [Abstract][Full Text] [Related]
8. Highly purified lipopolysaccharides from Burkholderia cepacia complex clinical isolates induce inflammatory cytokine responses via TLR4-mediated MAPK signalling pathways and activation of NFkappaB.
Bamford S; Ryley H; Jackson SK
Cell Microbiol; 2007 Feb; 9(2):532-43. PubMed ID: 17002785
[TBL] [Abstract][Full Text] [Related]
9. Burkholderia cenocepacia, B. multivorans, B. ambifaria and B. vietnamiensis isolates from cystic fibrosis patients have different profiles of exoenzyme production.
Carvalho AP; Ventura GM; Pereira CB; Leão RS; Folescu TW; Higa L; Teixeira LM; Plotkowski MC; Merquior VL; Albano RM; Marques EA
APMIS; 2007 Apr; 115(4):311-8. PubMed ID: 17504297
[TBL] [Abstract][Full Text] [Related]
10. Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe.
Coenye T; Spilker T; Van Schoor A; LiPuma JJ; Vandamme P
Thorax; 2004 Nov; 59(11):952-4. PubMed ID: 15516470
[TBL] [Abstract][Full Text] [Related]
11. [Burkholderia cepacia: dangers of a phytopathogen organism for patients with cystic fibrosis].
Segonds C; Chabanon G
Ann Biol Clin (Paris); 2001; 59(3):259-69. PubMed ID: 11397673
[TBL] [Abstract][Full Text] [Related]
12. First structural characterization of Burkholderia vietnamiensis lipooligosaccharide from cystic fibrosis-associated lung transplantation strains.
Ieranò T; Silipo A; Sturiale L; Garozzo D; Bryant C; Lanzetta R; Parrilli M; Aldridge C; Gould FK; Corris PA; Khan CM; De Soyza A; Molinaro A
Glycobiology; 2009 Nov; 19(11):1214-23. PubMed ID: 19641092
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa and Burkholderia cenocepacia infections in patients affected by cystic fibrosis: serum resistance and antibody response.
Savoia D; Deplano C; Zucca M
Immunol Invest; 2008; 37(1):19-27. PubMed ID: 18214797
[TBL] [Abstract][Full Text] [Related]
14. Exopolysaccharides produced by clinical strains belonging to the Burkholderia cepacia complex.
Herasimenka Y; Cescutti P; Impallomeni G; Campana S; Taccetti G; Ravenni N; Zanetti F; Rizzo R
J Cyst Fibros; 2007 Apr; 6(2):145-52. PubMed ID: 16860003
[TBL] [Abstract][Full Text] [Related]
15. Virulence of Burkholderia cepacia complex strains in gp91phox-/- mice.
Sousa SA; Ulrich M; Bragonzi A; Burke M; Worlitzsch D; Leitão JH; Meisner C; Eberl L; Sá-Correia I; Döring G
Cell Microbiol; 2007 Dec; 9(12):2817-25. PubMed ID: 17627623
[TBL] [Abstract][Full Text] [Related]
16. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.
Jones AM; Dodd ME; Govan JR; Barcus V; Doherty CJ; Morris J; Webb AK
Thorax; 2004 Nov; 59(11):948-51. PubMed ID: 15516469
[TBL] [Abstract][Full Text] [Related]
17. Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand.
Kidd TJ; Douglas JM; Bergh HA; Coulter C; Bell SC
Res Microbiol; 2008 Apr; 159(3):194-9. PubMed ID: 18356026
[TBL] [Abstract][Full Text] [Related]
18. Molecular approaches to pathogenesis study of Burkholderia cenocepacia, an important cystic fibrosis opportunistic bacterium.
Bazzini S; Udine C; Riccardi G
Appl Microbiol Biotechnol; 2011 Dec; 92(5):887-95. PubMed ID: 21997606
[TBL] [Abstract][Full Text] [Related]
19. Burkholderia cenocepacia lipopolysaccharide, lipid A, and proinflammatory activity.
De Soyza A; Ellis CD; Khan CM; Corris PA; Demarco de Hormaeche R
Am J Respir Crit Care Med; 2004 Jul; 170(1):70-7. PubMed ID: 15044201
[TBL] [Abstract][Full Text] [Related]
20. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology.
Mahenthiralingam E; Baldwin A; Dowson CG
J Appl Microbiol; 2008 Jun; 104(6):1539-51. PubMed ID: 18217926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
